AMGN Coverage Page 10
Meet the Preliminary Dogs of the Dow for 2022
Here is a look at the stocks currently in the running to be Dogs of the Dow for 2022.
Thursday Afternoon’s Analyst Upgrades and Downgrades: AbbVie, Occidental Petroleum, Pfizer, Yum! Brands and More
Thursday afternoon's top analyst upgrades and downgrades included AbbVie, Allstate, Amgen, Occidental Petroleum, Pfizer, SunPower, Twilio and Yum! Brands.
Biotech Has Been Crushed: 5 Stocks to Buy Now That Pay Big Dividends
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy…
Monday’s Top Analyst Upgrades and Downgrades: Apple, AT&T, Chevron, Dollar General, Ford, Kroger, Marvell, Peloton, Salesforce, Twitter and More
Monday’s top analyst upgrades and downgrades included Amgen, Apple, AT&T, Chevron, Dollar General, Fastly, Ford, Hertz, Kroger, Marvell Technology, Peloton Interactive, Salesforce.com, Stitch Fix and Twitter.
Friday Afternoon’s Analyst Upgrades and Downgrades: Alibaba, Amgen, Applied Materials, Delta Air, Macy’s, Snowflake, Walmart and More
Friday afternoon's analyst upgrades and downgrades included Alibaba, AIG, Amgen, Applied Materials, Bath & Body Works, Delta Air Lines, Kohl’s, Macy’s, Snowflake, Tapestry and Walmart.
Health Care Stocks Cheapest in 30 Years: 5 With Big Dividends to Buy Now
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate appreciation in…
5 Hard-Hit Dow Stocks Have Monster Upside and Come With Great Dividends
These five outstanding blue chip stocks have been hit hard this year and are offering growth and income investors incredible entry points and some big and, most importantly, reliable dividends. They are…
2 Large Cap Biotech Leaders Pay Big Dividends and Have Huge Upside Potential
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry points.
Thursday’s Top Analyst Upgrades and Downgrades: Amgen, Biogen, Commscope, Lockheed Martin, ONEOK, Plug Power, Roku and More
Thursday's top analyst upgrades and downgrades included Amgen, Biogen, Commscope, Lockheed Martin, Northrop Grumman, ONEOK, Plug Power and Roku.
Tuesday’s Top Analyst Upgrades and Downgrades: Amgen, Cirrus Logic, Johnson & Johnson, Lam Research, Merck, Spotify and Vertex Pharma
Tuesday’s top analyst upgrades and downgrades included Amgen, Cirrus Logic, Hain Celestial, Johnson & Johnson, Lam Research, Merck, Spotify Technology and Vertex Pharmaceuticals.
6 Stocks Marjorie Taylor Greene Is Buying
24/7 Wall St. takes a look at Georgia Representative Marjorie Taylor Greene and what stock trades are going on around her.
Goldman Sachs Has 4 Tech and Biotech Stocks to Buy With Big-Time Growth Potential
With the first quarter soon coming to an end, now is the time to move from momentum to strong growth stocks. Goldman Sachs feels these four could offer extra strength in a…
Amgen, Biogen, Gilead, Merck, Pfizer and More Health Care Earnings Coming This Week
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
2021’s Dogs of the Dow
The 2021 Dogs of the Dow are now known, and investors who may want to follow this investing strategy have got some thinking to do.